
Paolo de Fabritiis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3274188/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances, 2022, 6, 1742-1753.	5.2	33
2	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. Blood Advances, 2022, 6, 2510-2516.	5.2	3
3	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. Frontiers in Oncology, 2022, 12, 826040.	2.8	5
4	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. Journal of Clinical Medicine, 2022, 11, 1801.	2.4	10
5	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica, 2021, 106, 2345-2353.	3.5	8
6	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica, 2021, 106, 1559-1568.	3.5	49
7	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73.	6.2	7
8	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clinical Cancer Research, 2021, 27, 3695-3703.	7.0	7
9	New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine. Future Oncology, 2021, 17, 1973-1975.	2.4	0
10	Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach. Frontiers in Oncology, 2021, 11, 699886.	2.8	0
11	CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 2021, 13, 3214.	3.7	20
12	Major Differences in Lymphocyte Subpopulations Between Cerebrospinal Fluid and Peripheral Blood in Non-Hodgkin Lymphoma Without Leptomeningeal Involvement: Flow Cytometry Evidence of a Cerebral Lymphatic System. Frontiers in Oncology, 2021, 11, 685786.	2.8	4
13	Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra― Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S153-S155.	0.4	1
14	Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph'+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib. Chemotherapy, 2021, 66, 78-81.	1.6	0
15	OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S34.	0.4	2
16	Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. Blood, 2021, 138, 4017-4017.	1.4	1
17	Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2021, 138, 2359-2359.	1.4	1
18	INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4391-4391.	1.4	1

#	ARTICLE Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus	IF	CITATIONS
19	autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncology, The,	10.7	120
20	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematological Oncology, 2020, 38, 189-196.	1.7	6
21	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	4.6	34
22	Impact of SARS CoV-2 in hemoglobinopathies: a protective mechanism being from Beta chain Hemoglobin defects?. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020052.	1.3	12
23	NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020083.	1.3	6
24	SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020031.	1.3	30
25	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. Blood Cancer Journal, 2020, 10, 58.	6.2	9
26	SARS oVâ€2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies. British Journal of Haematology, 2020, 190, e5-e8.	2.5	31
27	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1113-1118.	2.0	3
28	TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?. Frontiers in Oncology, 2020, 10, 610820.	2.8	38
29	Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients. Blood, 2020, 136, 54-54.	1.4	1
30	Favorable kidney recovery by extracorporeal light chain removal and anti-myeloma treatments in patients with newly diagnosed multiple myeloma and acute renal failure. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2020, 31, 1445.	0.3	0
31	Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy. Blood, 2020, 136, 35-37.	1.4	4
32	Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis. Blood, 2020, 136, 11-12.	1.4	1
33	New Perspectives and Challenges Regarding Fertility, Conception and Pregnancy in Hemoglobinopathies. a Multidisciplinary Report of 66 Outcomes. Blood, 2020, 136, 22-23.	1.4	0
34	Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol. Blood, 2020, 136, 34-35.	1.4	0
35	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	1.3	7
36	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood, 2019, 134, 935-945.	1.4	148

#	Article	IF	CITATIONS
37	Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy. Acta Oncológica, 2019, 58, 888-890.	1.8	2
38	Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation. Blood Research, 2019, 54, 288-290.	1.3	0
39	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Supportive Care in Cancer, 2019, 27, 793-803.	2.2	8
40	Back to the future: Treatmentâ€free remission and pregnancy in chronic myeloid leukemia. European Journal of Haematology, 2019, 102, 197-199.	2.2	15
41	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	1.4	11
42	Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA). Blood, 2019, 134, 1744-1744.	1.4	0
43	Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient. Acta Haematologica, 2018, 139, 58-59.	1.4	Ο
44	Is cell therapy the answer for hematological malignancies?. Expert Opinion on Biological Therapy, 2018, 18, 495-497.	3.1	0
45	Gender, age and diagnosis effect on self-perceived pain in hematological patients: retrospective analysis of two case series. Annals of Palliative Medicine, 2018, 7, 484-486.	1.2	Ο
46	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. Acta Haematologica, 2018, 140, 231-233.	1.4	5
47	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.4	61
48	Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. American Journal of Hematology, 2018, 93, E243-E246.	4.1	48
49	Chronic myeloproliferative disorders: is quality-of-life the new goal?. Current Medical Research and Opinion, 2018, 34, 1345-1347.	1.9	2
50	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4396-4396.	1.4	2
51	Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). Blood, 2018, 132, 4244-4244.	1.4	2
52	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4397-4397.	1.4	3
53	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study. Blood, 2018, 132, 3147-3147.	1.4	1
54	Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Acta Oncológica, 2017, 56, 1120-1121.	1.8	3

#	Article	IF	CITATIONS
55	Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Acta Oncológica, 2017, 56, 1331-1333.	1.8	7
56	Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. Annals of Hematology, 2017, 96, 1591-1593.	1.8	3
57	Hodgkin's lymphoma in a man with dilated cardiomyopathy and paraneoplastic ataxia: a therapeutical challenge. Hematology Reports, 2017, 9, 6944.	0.8	1
58	Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?. Blood Research, 2017, 52, 218.	1.3	2
59	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2017, 130, 99-99.	1.4	63
60	At-Home Application of Autologous Platelet Rich Plasma as Treatment for Pressure Sore and Related Anemia. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 14, 90-93.	1.0	3
61	Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. Blood Research, 2016, 51, 137.	1.3	1
62	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017046.	1.3	3
63	Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?. Blood Research, 2016, 51, 66.	1.3	0
64	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica, 2016, 101, 1544-1552.	3.5	72
65	Primitive "Spindle Cell Variant―(Sarcomatoid Variant) Diffuse Large B-Cell Lymphoma of the Uterine Cervix: Description and Outcome of a Rare Case. International Journal of Gynecological Pathology, 2016, 35, 593-597.	1.4	10
66	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	3.5	53
67	Patientâ€reported outcomes and quality of life assessment: New targets for new targeted therapy?. Cancer, 2016, 122, 1461-1462.	4.1	2
68	Management of pregnant chronic myeloidÂleukemia patients. Expert Review of Hematology, 2016, 9, 781-791.	2.2	55
69	Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome?. Leukemia Research, 2016, 42, 80-81.	0.8	0
70	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leukemia Research, 2016, 41, 36-42.	0.8	41
71	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of Clinical Oncology, 2016, 34, 972-979.	1.6	296
72	Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. Bone Marrow Transplantation, 2016, 51, 638-639.	2.4	0

#	Article	IF	CITATIONS
73	Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma. Supportive Care in Cancer, 2016, 24, 9-10.	2.2	2
74	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	1.4	3
75	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs of Today, 2016, 52, 249.	1.1	18
76	Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency. Turkish Journal of Haematology, 2016, 33, 77-78.	0.5	1
77	Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 3204-3204.	1.4	0
78	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	1.4	1
79	Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. Journal of Experimental and Clinical Cancer Research, 2015, 34, 98.	8.6	15
80	Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent. Blood Research, 2015, 50, 113.	1.3	1
81	Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia. Blood Research, 2015, 50, 181.	1.3	Ο
82	Clinical Complications in Outpatient Myelodysplastic Syndromes. Home Health Care Management and Practice, 2015, 27, 18-23.	1.0	0
83	Dismal Outcome of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia after Azacitidine Failure in a Daily-Life Setting. Acta Haematologica, 2015, 133, 64-66.	1.4	7
84	Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders. Annals of Hematology, 2015, 94, 1753-1754.	1.8	3
85	Caring for terminal patients in haematology: the urgent need of a new research agenda. Supportive Care in Cancer, 2015, 23, 5-7.	2.2	14
86	Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Supportive Care in Cancer, 2015, 23, 2211-2211.	2.2	6
87	Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders. Supportive Care in Cancer, 2015, 23, 303-305.	2.2	10
88	Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia. Blood, 2015, 126, 2004-2004.	1.4	0
89	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 1718-1718.	1.4	0
90	Bone marrow aspiration and biopsy-related pain management. Annals of Hematology, 2014, 93, 1061-2.	1.8	3

#	Article	IF	CITATIONS
91	Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy. Blood Research, 2014, 49, 65.	1.3	5
92	TYROSINE KINASE INHIBITORS AND PREGNANCY. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014028.	1.3	91
93	Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy. Blood Research, 2014, 49, 130.	1.3	1
94	AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014020.	1.3	11
95	Pure erythroid leukemia in advanced breast cancer. Blood Research, 2014, 49, 69.	1.3	1
96	An unusual case of follicular dendritic cell sarcoma of the omentum with pleomorphous morphology and aberrant cytokeratin expression. Journal of Hematopathology, 2014, 7, 177-180.	0.4	1
97	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer: comment. Journal of Thrombosis and Haemostasis, 2014, 12, 805-807.	3.8	2
98	High incidence of postâ€ŧransplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomibâ€based regimens: a survey from the Rome Transplant Network. Transplant Infectious Disease, 2014, 16, 158-164.	1.7	38
99	Fibrin Glue Therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1612-1617.	2.0	35
100	Making quality of life assessment a dashboard for patient management. Supportive Care in Cancer, 2014, 22, 2311-2312.	2.2	3
101	Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab. Annals of Hematology, 2014, 93, 863-865.	1.8	3
102	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology, 2014, 93, 1765-1774.	1.8	34
103	Motor disability, clinical complications, quality of life, and survival in patients with cancer: a plausible scenario. Supportive Care in Cancer, 2014, 22, 2603-2604.	2.2	2
104	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood, 2014, 124, 2930-2936.	1.4	268
105	Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood, 2014, 124, 1806-1806.	1.4	5
106	Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors. Blood, 2014, 124, 5668-5668.	1.4	1
107	Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups. Blood. 2014. 124. 619-619.	1.4	9
108	Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfusion, 2014, , 1-3.	0.4	2

#	Article	IF	CITATIONS
109	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. Blood, 2014, 124, 1794-1794.	1.4	1
110	Clinical Significance of Apoptosis in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 834-834.	1.4	0
111	Predictors of Outcome and Response to Therapy in Primary Autoimmune Hemolytic Anemia: A Gimema Study of 307 Patients. Blood, 2014, 124, 1346-1346.	1.4	ο
112	Survival of Patients with High Risk Hematological Malignancy after Allogeneic Transplant from HLA Identical Siblings Is Comparable to That of Patients Transplanted from Haploidentical, Unmanipulated Bone Marrow Donor: Results of a Matched-Pair Analysis from the Rome Transplant Network. Blood, 2014, 124, 1223-1223.	1.4	0
113	Durable erythroid response after discontinuation of epoetin-alpha: an unexpected outcome in a patient with myelodysplastic syndrome. Blood Transfusion, 2014, 12 Suppl 1, s160-1.	0.4	1
114	Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfusion, 2014, 12, 605-7.	0.4	6
115	Accidental falls in home care hematological patients. Supportive Care in Cancer, 2013, 21, 2087-2089.	2.2	6
116	Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes. Supportive Care in Cancer, 2013, 21, 1803-1805.	2.2	0
117	Gingival myeloid sarcoma in myelodysplastic syndrome. Supportive Care in Cancer, 2013, 21, 917-918.	2.2	7
118	Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Supportive Care in Cancer, 2013, 21, 5-6.	2.2	6
119	Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence. Supportive Care in Cancer, 2013, 21, 365-366.	2.2	7
120	Quality-of-Life Monitoring During Hematopoietic Stem Cell Transplantation: Observations and a Suggestion From the Rome Transplant Network Quality of Life Working Party. Journal of Pain and Symptom Management, 2013, 45, e2-e3.	1.2	6
121	Reduction in the Risk Invasive Fungal Infection Relapse in Patients Undergoing Allogenic Stem Cell Transplantation Using Caspofunginas Secondary Prophylaxis. , 2013, , 253-262.		О
122	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). Journal of Clinical Oncology, 2013, 31, 4424-4430.	1.6	78
123	Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013030.	1.3	3
124	Primary pulmonary Hodgkin Lymphoma simulating a mediastinal tumour: an uncommon occurrence Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013013.	1.3	3
125	Antifungal Drugs in the Management of Hematological Diseases in a Home Care Program. Home Health Care Management and Practice, 2013, 25, 247-249.	1.0	1
126	Access to Holiday in Hematological Patients Managed in a Home Care Program. Home Health Care Management and Practice, 2013, 25, 62-63.	1.0	0

#	Article	IF	CITATIONS
127	Dysgeusia in patients with hematological malignancies: a reminder for hematologist. Journal of Oral Pathology and Medicine, 2013, 42, 352-353.	2.7	0
128	Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab–bendamustine regimen combined to hypomethylating therapy. Journal of Chemotherapy, 2013, 25, 247-249.	1.5	1
129	The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2013, 11, 67-76.	1.0	18
130	Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association. Blood Research, 2013, 48, 292.	1.3	2
131	Managing myelodysplastic syndromes in very old patients: a teaching case report. Clinical Interventions in Aging, 2013, 8, 391.	2.9	5
132	Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis. Blood Research, 2013, 48, 228.	1.3	3
133	Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia. Blood Research, 2013, 48, 297.	1.3	2
134	Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Research, 2013, 48, 152.	1.3	3
135	Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Blood Research, 2013, 48, 296.	1.3	5
136	IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome. Asian Journal of Transfusion Science, 2012, 6, 188.	0.3	1
137	Single versus double-unit transfusion policy in hematology. Haematologica, 2012, 97, e25-e25.	3.5	0
138	The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 362-375.	1.0	4
139	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012, 97, 279-287.	3.5	32
140	Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. European Journal of Haematology, 2012, 89, 276-277.	2.2	14
141	Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin. The Korean Journal of Hematology, 2012, 47, 309.	0.7	3
142	Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Supportive Care in Cancer, 2012, 20, 891-892.	2.2	10
143	Lenalidomide cutaneous adverse event: a case of Stevens–Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Supportive Care in Cancer, 2012, 20, 1585-1587.	2.2	6
144	Transfusions at home in patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 684-688.	0.8	28

#	Article	IF	CITATIONS
145	Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 135-147.	1.0	3
146	Fever of unknown origin, anemia and thrombocytosis as early symptoms and signs of a late-onset polymialgia rheumatica: A diagnostic challenge. Annals of Saudi Medicine, 2012, 32, 322-323.	1.1	0
147	Controversies on Antibiotic Lock Technique Duration Experience with a 3-Day Course for Hematological Patients. Infection Control and Hospital Epidemiology, 2011, 32, 408-410.	1.8	3
148	Tattoo related pyoderma/ectyma gangrenous as presenting feature of relapsed acute myeloid leukaemia: An exceptionally rare observation. Injury, 2011, 42, 546-547.	1.7	17
149	Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience. Annals of Hematology, 2011, 90, 115-116.	1.8	6
150	Epidemiology and pathogenesis of incident pain-related disability in malignant hematology: an Italian survey. Annals of Hematology, 2011, 90, 719-720.	1.8	6
151	Motor disability in the setting of oral anticoagulant therapy. International Journal of Hematology, 2011, 94, 499-500.	1.6	4
152	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. Leukemia and Lymphoma, 2011, 52, 2329-2335.	1.3	7
153	Management of hematological malignancies in patients affected by renal failure. Expert Review of Anticancer Therapy, 2011, 11, 415-432.	2.4	7
154	Idiopathic thrombocytopenic purpura coexisting with polycythemia vera. Asian Journal of Transfusion Science, 2011, 5, 187.	0.3	1
155	Anticoagulant and anti-thrombotic treatments in the management of hematological malignancies in a home care program. Indian Journal of Palliative Care, 2011, 17, 54.	1.0	8
156	Homecare-based motor rehabilitation in musculoskeletal chronic graft versus host disease. Indian Journal of Palliative Care, 2011, 17, 159.	1.0	6
157	Management of peritoneal dialysis within a home care program for hematological malignancies: Concerns and perspectives illustrated by a case report. Indian Journal of Palliative Care, 2011, 17, 166.	1.0	1
158	Authors' reply. Indian Journal of Palliative Care, 2011, 17, 260-1.	1.0	1
159	Sleep Complaints in Hospitalized Italian Patients with Hematological Malignancies. Internal Medicine, 2010, 49, 1689-1689.	0.7	3
160	Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease. Annals of Hematology, 2010, 89, 821-822.	1.8	6
161	Pancytopenia and severe sepsis in an adult case of congenital X-linked agammaglobulinemia (XLA). Annals of Hematology, 2010, 89, 949-951.	1.8	0
162	Koebner's phenomenon as a rare mechanism of acute myeloid leukemia dissemination: report of two cases with a brief overview. Supportive Care in Cancer, 2010, 18, 1495-1497.	2.2	1

#	Article	IF	CITATIONS
163	IgG secreting lymphoplasmacytoid leukemia with massive skin involvement and very aggressive clinical course: An exceptionally rare observation. Leukemia Research, 2010, 34, e58-e59.	0.8	2
164	Motor disability in malignant hematology: An epidemiological study on Italian hospitalized patients. Leukemia Research, 2010, 34, e66.	0.8	12
165	The genotype nucleophosmin mutated and <i>FLT3</i> â€ITD negative is characterized by high bax/bclâ€2 ratio and favourable outcome in acute myeloid leukaemia. British Journal of Haematology, 2010, 149, 383-387.	2.5	15
166	Cold autoimmune hemolytic anemia resolved by rituximab. Asian Journal of Transfusion Science, 2010, 4, 136.	0.3	1
167	Pain management in multiple myeloma. Expert Review of Anticancer Therapy, 2010, 10, 415-425.	2.4	26
168	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 95-106.	1.3	16
169	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806 Blood, 2010, 116, 3412-3412.	1.4	0
170	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. Blood, 2010, 116, 4848-4848.	1.4	9
171	Long-lasting remission of a relapsed large cell non-Hodgkin's lymphoma by Y90 ibritumomab tiuxetan as salvage therapy. Tumori, 2009, 95, 129-130.	1.1	3
172	Long-Term Favorable Results by Arteriovenous Graft with Omniflow II Prosthesis for Hemodialysis. Nephron Clinical Practice, 2009, 113, c76-c80.	2.3	37
173	Unusual sequence of lymphoid disorders: Follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma. Acta Oncológica, 2009, 48, 1073-1074.	1.8	1
174	Isolated bone involvement of a single lumbar vertebra body as unusual presentation of relapsing Hodgkin's lymphoma. Acta OncolA³gica, 2009, 48, 1085-1086.	1.8	0
175	Palliative sedation therapy in a bone marrow transplant unit. Supportive Care in Cancer, 2009, 17, 107-108.	2.2	3
176	Bortezomib-related colon mucositis in a multiple myeloma patient. Supportive Care in Cancer, 2009, 17, 325-327.	2.2	13
177	Disability and physical rehabilitation in patients with advanced hematological malignancies followed in a home care program. Supportive Care in Cancer, 2009, 17, 1559-1560.	2.2	19
178	Primary MALT lymphoma of the upper lip mucosa: an exceptionally rare localisation. International Journal of Hematology, 2009, 89, 130-131.	1.6	4
179	Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura. International Journal of Hematology, 2009, 89, 398-399.	1.6	8
180	High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. International Journal of Hematology, 2009, 90, 270-272.	1.6	4

#	Article	IF	CITATIONS
181	Feasibility of a dose-adjusted fludarabine–melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Annals of Hematology, 2009, 88, 285-286.	1.8	11
182	Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis. Cancer Chemotherapy and Pharmacology, 2009, 63, 759-760.	2.3	5
183	High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia. Bone Marrow Transplantation, 2009, 43, 587-588.	2.4	17
184	Pain Syndromes in Sickle Cell Disease: An Update. Pain Medicine, 2009, 10, 470-480.	1.9	52
185	Multicentric myeloid/NK sarcoma in an aleukemic patient evolved in refractory acute leukemia. Leukemia Research, 2009, 33, 1294-1296.	0.8	2
186	Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leukemia and Lymphoma, 2009, 50, 387-391.	1.3	50
187	Palifermin in theManagement of Mucositis in Hematological Malignancies: Current Evidences and Future Perspectives. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 305-312.	1.0	11
188	Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer. BMJ Case Reports, 2009, 2008, bcr0320091715-bcr0320091715.	0.5	3
189	Long term follow-up of a membranous glomerulopathy as late complication of chronic graft-versus-host disease following allogeneic stem cell transplantation. International Journal of Hematology, 2008, 87, 449-450.	1.6	3
190	Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. International Journal of Hematology, 2008, 88, 343-344.	1.6	2
191	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with Bâ€cell chronic lymphocytic leukemia. Cancer, 2008, 112, 119-128.	4.1	86
192	Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient. Leukemia Research, 2008, 32, 363-365.	0.8	2
193	Epidemiology of pain in hospital haematological setting: An Italian survey. Leukemia Research, 2008, 32, 197-198.	0.8	21
194	Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplantation, 2008, 41, 757-764.	2.4	44
195	Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 4944-4951.	1.6	165
196	Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leukemia and Lymphoma, 2007, 48, 759-766.	1.3	27
197	Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab. Leukemia and Lymphoma, 2007, 48, 1878-1880.	1.3	6
198	Gelatinous Degeneration of the Bone Marrow: Two Case Reports Showing Different Hematological Features and Clinical Outcomes. Acta Haematologica, 2007, 118, 165-166.	1.4	5

#	Article	IF	CITATIONS
199	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica, 2007, 92, 605-611.	3.5	76
200	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer, 2007, 109, 2466-2472.	4.1	29
201	Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplantation, 2007, 40, 245-249.	2.4	46
202	Mucositis in patients with hematologic malignancies: an overview. Haematologica, 2007, 92, 222-231.	3.5	82
203	Bone Marrow Necrosis as a Terminal Complication of a Very Long-Lasting Polycythemia Vera. International Journal of Hematology, 2007, 86, 377-378.	1.6	1
204	Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Annals of Hematology, 2007, 86, 671-676.	1.8	44
205	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 2006, 108, 853-861.	1.4	171
206	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nature Clinical Practice Oncology, 2006, 3, 374-387.	4.3	103
207	Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. Blood, 2006, 107, 4571-4572.	1.4	7
208	A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infectious Diseases, 2006, 6, 167.	2.9	30
209	Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. Annals of Hematology, 2006, 85, 136-138.	1.8	5
210	Opioids in pain management of blood-related malignancies. Annals of Hematology, 2006, 85, 489-501.	1.8	19
211	Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. Hematology, 2006, 11, 171-177.	1.5	2
212	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy Blood, 2006, 108, 2116-2116.	1.4	0
213	Epidemiology and Characteristics of Pain in Patients Suffering from Advanced Haematological Malignancies in the Home Care (HC) Setting: An Italian Survey Blood, 2006, 108, 5502-5502.	1.4	0
214	Epidemiology and Characteristics of Pain in Blood-Related Disorders: A Longitudinal Study on Italian Adult Hospitalized Patients Blood, 2006, 108, 5501-5501.	1.4	0
215	Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib,) Tj ETQq1 1	0.78 4.3 14 r	gBT0/Overloct
216	Acute Zoster Pain (AZP) and Post-Herpetic Neuralgia (PHN) in the Course of Lymphoproliferative Disorders (LPD): Durable Pain Relief Provided by Oxycodone in Patients Unresponsive to Standard Therapy Blood, 2006, 108, 5500-5500.	1.4	0

#	Article	IF	CITATIONS
217	Home care management of patients affected by hematologic malignancies: a review. Haematologica, 2006, 91, 1523-9.	3.5	17
218	Breakthrough Fusariosis in a Patient with Acute Lymphoblastic Leukemia Receiving Voriconazole Prophylaxis. Clinical Infectious Diseases, 2005, 40, 1212-1213.	5.8	37
219	Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. The Hematology Journal, 2004, 5, 24-31.	1.4	6
220	Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leukemia Research, 2004, 28, 1165-1169.	0.8	100
221	Intermediate-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor Is a Valid Alternative to High-Dose Cyclophosphamide for Mobilizing Peripheral Blood CD34+ Cells in Patients with Multiple Myeloma. Acta Haematologica, 2003, 109, 184-188.	1.4	25
222	Possibility of Progenitor Cell Mobilization during the Hematological Recovery following Peripheral Blood Stem Cell Autograft. Acta Haematologica, 2003, 109, 57-63.	1.4	0
223	Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood, 2002, 100, 1065-1067.	1.4	69
224	Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemotherapy and Pharmacology, 2001, 47, 361-369.	2.3	26
225	CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion, 2001, 41, 190-195.	1.6	22
226	Phenotypic Characterization of Normal and CML CD34–Positive Cells: Only the Most Primitive CML Progenitors Include Ph-neg Cells. Leukemia and Lymphoma, 1993, 11, 51-61.	1.3	2
227	Pharmacological purging of syngeneic bone marrow ex vivo: Effect of treatment with doxorubicin and lonidamine on normal and leukaemic cells of mice. European Journal of Cancer, 1992, 28, 1633-1636.	2.8	2
228	CD9 antigen on acute non-lymphoid leukemia cells: Preferential expression by promyelocytic (M3) subtype. Leukemia Research, 1991, 15, 457-461.	0.8	7
229	In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine. Experimental and Molecular Pathology, 1989, 50, 210-219.	2.1	9
230	Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. Leukemia Research, 1987, 11, 265-272.	0.8	14
231	Antigenic heterogeneity among burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leukemia Research, 1986, 10, 35-42.	0.8	9
232	Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse. Leukemia Research, 1985, 9, 407-412.	0.8	28